OLIVIA GIBSON-DELANEY: Open Payments
NPI 1881128924 · MONTCLAIR, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$427 in 24 payments from 11 companies in 2025. Trend: 2023 $587 · 2024 $571 · 2025 $427
Food & beverage: $427
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $88 |
| Alkermes, Inc. | 4 | $70 |
| Neurocrine BioSciences, Inc. | 3 | $58 |
| Janssen Pharmaceuticals, Inc | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Lundbeck LLC | 1 | $18 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Bausch Health US, LLC | 1 | $16 |
Products named: VRAYLAR, ARISTADA, INGREZZA, INVEGA SUSTENNA, REXULTI, ERZOFRI EXTENDED-RELEASE, COBENFY, AUSTEDO XR.
Industry payments across NJ — which companies pay providers there.
